DEA Places Suvorexant into Schedule IV
The Drug Enforcement Administration placed the insomnia drug suvorexant into Schedule IV of the Controlled Substances Act. The Food and Drug Administration recently approved the drug on Aug. 13, said DEA. Effective Sept. 29, suvorexant will be subject to new registration, labeling, recordkeeping, and import and export requirements.
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
(Federal Register 08/28/14)